Financial Performance - Expected consolidated revenues for Q4 2025 are at least $261 million, up from $248 million in Q4 2024, representing a growth of approximately 5.2%[3] - Expected Adjusted EBITDA for Q4 2025 is at least $63 million, an increase from $53.7 million in Q4 2024, reflecting a growth of about 17.5%[3] - Expected full year 2026 consolidated revenues are projected to be between $1.045 billion and $1.097 billion, compared to $948.9 million in 2025, indicating a growth of at least 10.2%[11] - Expected Adjusted EBITDA for 2026 is projected to be between $234 million and $242 million, which includes approximately $7 million of public company costs not incurred in 2025[11] - Expected net loss for 2025 is not larger than $25.4 million, compared to a net loss of $25.1 million in 2024[3] Operational Metrics - Total outpatient procedures for 2025 reached 2,418,096, a 4.6% increase from 2,312,645 in 2024[5] - System-wide total procedures for Q4 2025 were 1,027,590, a 6.8% increase from 962,520 in Q4 2024[5] - Full year PET imaging volumes increased by 17.0% on a consolidated basis, supported by the adoption of radiopharmaceuticals[9] - The percentage of advanced procedures increased to 30.1% in 2025 from 29.2% in 2024, reflecting a 90 basis points improvement[5] Expansion Activities - The company opened 9 de novo centers in 2025, including 6 wholly owned and 3 through joint ventures, and completed one acquisition[6]
Lumexa Imaging Holdings(LMRI) - 2025 Q4 - Annual Results